Microbot Medical is transitioning from R&D to commercialization with its LIBERTY single-use robotic system for endovascular interventions. I assign MBOT a neutral rating with a 1-year price target of ...

Fintel reports that on December 3, 2025, Roth Capital initiated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 453.85% Upside As of November 17 ...

KUALA LUMPUR: Over 100,000 technologists and technicians including those specialising in emerging technologies are currently registered under the Malaysia Board of Technologists (MBOT), says Chang Lih ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Microbot Medical ( (MBOT)) just unveiled ...

Fintel reports that on October 15, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 325.00% Upside As of ...

HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY ® Endovascular Robotic System, announces that its Chief ...

We recently published 10 Stocks Losing Big Amid Market Boom. Microbot Medical Inc. (NASDAQ:MBOT) is one of the worst performers on Thursday. Microbot extended its losing streak to a fourth consecutive ...

Microbot Medical announced that the U.S. FDA has granted 510(k) clearance for its LIBERTY® System, the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular ...

MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...